JAK2 and chordoma: To test this, we measured the sensitivity of chordoma cells to the pan-JAK inhibitor filgotinib (46); the JAK2 inhibitors AZD1480 (46), fedratinib (46), and pacritinib (46); the chemotherapeutic and STAT1 inhibitor fludarabine (47); and the FLT3 inhibitor gilteritinib as a control (48), because fedratinib and pacritinib also inhibit FLT3.